Effect of Probiotic Administration on Serum Tryptophan Metabolites in Pediatric Type 1 Diabetes Patients

Mondanelli, Giada; Orecchini, Elena; Volpi, Claudia; Panfili, Eleonora; Belladonna, Maria Laura; Pallotta, Maria Teresa; Moretti, Simone; Galarini, Roberta; Esposito, Susanna; Orabona, Ciriana

doi:10.1177/1178646920956646

Cited by 15 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pathway analysis using imputed metagenomics based on 16S rRNA sequences revealed tryptophan metabolism as significantly decreased ( q value = 0.045) in group 3 compared with group 1 ( Supplemental Fig. 3 ), which has also been described in T1D patients and mouse model ( 39 ).…”

Section: Resultssupporting

confidence: 55%

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti–PD-1

Patel,

Becker,

Ploix

et al. 2023

ImmunoHorizons

View full text Add to dashboard Cite

Our bodies are home to individual-specific microbial ecosystems that have recently been found to be modified by cancer immunotherapies. The interaction between the gut microbiome and islet autoimmunity leading to type I diabetes (T1D) is well described and highlights the microbiome contribution during the onset and T1D development in animals and humans. As cancer immunotherapies induce gut microbiome perturbations and immune-mediated adverse events in susceptible patients, we hypothesized that NOD mice can be used as a predictive tool to investigate the effects of anti–PD-1 treatment on the onset and severity of T1D, and how microbiota influences immunopathology. In this longitudinal study, we showed that anti–PD-1 accelerated T1D onset, increased glutamic acid decarboxylase–reactive T cell frequency in spleen, and precipitated destruction of β cells, triggering high glucose levels and pancreatic islet reduction. Anti–PD-1 treatment also resulted in temporal microbiota changes and lower diversity characteristic of T1D. Finally, we identified known insulin-resistance regulating bacteria that were negatively correlated with glucose levels, indicating that anti–PD-1 treatment impacts the early gut microbiota composition. Moreover, an increase of mucin-degrading Akkermansia muciniphila points to alterations of barrier function and immune system activation. These results highlight the ability of microbiota to readily respond to therapy-triggered pathophysiological changes as rescuers (Bacteroides acidifaciens and Parabacteroides goldsteinii) or potential exacerbators (A. muciniphila). Microbiome-modulating interventions may thus be promising mitigation strategies for immunotherapies with high risk of immune-mediated adverse events.

show abstract

Section: Resultssupporting

confidence: 55%

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti–PD-1

Patel,

Becker,

Ploix

et al. 2023

ImmunoHorizons

View full text Add to dashboard Cite

show abstract

“…To what extent the intake of probiotics could increase the production of these compounds with anticancer properties is still uncertain. As mentioned before, probiotics express bile salt hydrolase and increase bile salt metabolism in the gut; an increase in indole-3-propionic acid was observed in rats treated with probiotics [66] but not in children affected with type I diabetes [67]. Increased levels of polyamines have been demonstrated in the elderly after treatment with bifidobacteriacontaining synbiotics [68].…”

Section: Rationale For the Use Of Probiotics In The Treatment Of The ...mentioning

confidence: 70%

Probiotics and Prebiotics: Any Role in Menopause-Related Diseases?

et al. 2023

View full text Add to dashboard Cite

Purpose of Review The aim of this review is to provide an overview of the menopause-related changes in microbiota and their role in the pathogenesis of menopause-related diseases. In addition, evidence on probiotic supplementation as a therapeutic strategy is discussed. Recent Findings The human microbiota is a complex community that lives in a mutualism relationship with the host. Menopause is associated with dysbiosis, and these changes in the composition of microbiota in different sites (gut, vaginal, and oral microbiota) might play a role in the pathogenesis of menopause-related diseases (i.e., osteoporosis, breast cancer, endometrial hyperplasia, periodontitis, and cardiometabolic diseases). Summary The present review highlights the pivotal role of microbiota in postmenopausal women health, in particular it (a) may increase intestinal calcium absorption thus preventing osteoporosis, (b) is associated with reduced risk of breast cancer and type 1 endometrial hyperplasia, (c) reduces gingival inflammation and menopausal periodontitis, and (d) beneficially affects multiple cardiometabolic risk factors (i.e., obesity, inflammation, and blood glucose and lipid metabolism). However, whether oral probiotic supplementation might be used for the treatment of menopause-related dysbiosis requires further clarification.

show abstract

“…A prospective cohort study of 7,473 children showed that early probiotic supplementation could reduce the risk of islet autoimmunity in children at the highest genetic risk of T1DM ( 200 ). Another study of 61 young T1DM patients given either Lactobacillus rhamnosus GG or placebo daily for 12 weeks showed that intake of probiotics significantly increased circulating levels of tryptophan and decreased inflammatory cytokine production ( 201 ). The results of a recent randomized, double-blind, and placebo-controlled pilot study assessing treatment with a multispecies probiotic preparation, in 90 children with new-onset T1DM showed that better glycemic control and a decrease in insulin requirements ( 202 ).…”

Section: Gut Microbiome-target Therapiesmentioning

confidence: 99%

Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target

et al. 2022

View full text Add to dashboard Cite

Pancreatic-related disorders such as pancreatitis, pancreatic cancer, and type 1 diabetes mellitus (T1DM) impose a substantial challenge to human health and wellbeing. Even though our understanding of the initiation and progression of pancreatic diseases has broadened over time, no effective therapeutics is yet available for these disorders. Mounting evidence suggests that gut dysbiosis is closely related to human health and disease, and pancreatic diseases are no exception. Now much effort is under way to explore the correlation and eventually potential causation between the gut microbiome and the course of pancreatic diseases, as well as to develop novel preventive and/or therapeutic strategies of targeted microbiome modulation by probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) for these multifactorial disorders. Attempts to dissect the intestinal microbial landscape and its metabolic profile might enable deep insight into a holistic picture of these complex conditions. This article aims to review the subtle yet intimate nexus loop between the gut microbiome and pancreatic diseases, with a particular focus on current evidence supporting the feasibility of preventing and controlling pancreatic diseases via microbiome-based therapeutics and therapies.

show abstract

Effect of Probiotic Administration on Serum Tryptophan Metabolites in Pediatric Type 1 Diabetes Patients

Cited by 15 publications

References 30 publications

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti–PD-1

Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti–PD-1

Probiotics and Prebiotics: Any Role in Menopause-Related Diseases?

Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target

Contact Info

Product

Resources

About